AbbVie Canada and adMare BioInnovations awarded RIME Therapeutics the AbbVie Biotech Innovators Award, supporting Quebec's biotech ecosystem. Founded in 2025, RIME develops a peptide-based drug discovery platform targeting inflammation and immune disorders. The award grants RIME free lab and office space for a year at adMare's Montreal Innovation Centre, plus access to AbbVie's executive mentorship. This support aims to accelerate RIME's innovative research and development of new treatments for immune-related diseases in Canada.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
